Yen-Ching Ho

Yen-Ching Ho has a strong background in scientific research and drug discovery. They started their career at GPC Biotech in 2002 as a Scientist II, where they conducted studies to determine the mode of action and efficacy of novel compounds. At GPC Biotech, Yen-Ching also discovered a novel substrate for a kinase target through biochemical purification and bioinformatics.

In 2008, Yen-Ching joined FORMA Therapeutics, Inc. as a Scientist. During their time at FORMA Therapeutics, they generated in vitro data that led to a collaboration with Genentech. They also developed novel biochemical and cellular assays for various targets. Yen-Ching progressed to the role of Senior Scientist, where they managed a team and served as the Biology Lead for a protein homeostasis program. Additionally, they revived a metabolism program using novel methodology that alleviated on-target toxicities. Eventually, Yen-Ching became a Principal Scientist at FORMA Therapeutics, leading a team of junior scientists and serving as the Biology Project Lead for successful drug discovery programs. They also collaborated with academic partners for target validation projects.

In 2019, Yen-Ching explored new opportunities before joining Orionis Biosciences as a Principal Scientist.

Yen-Ching Ho began their education in the field of Biology at the Massachusetts Institute of Technology, where they obtained a Bachelor of Science degree from 1988 to 1992. Building on this foundation, they pursued further studies at Harvard University from 1994 to 2002, where they obtained a Ph.D. in Molecular and Cellular Biology.